Tumor-associated-antigens or osteosarcoma cell line lysates: Two efficient methods for in vitro generation of CTLs with special regard to MHC-I restriction

Cellular Immunology

Volumn 266, Issue 2, 2011, Pages 123-129

  Muraro, Michela ^a   Mereuta, Oana Madalina ^a   Saglio, Francesco ^a   Carraro, Francesca ^a   Cravero, Cristina ^a   Fagioli, Franca ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

CTLs; MAGE; Osteosarcoma cell line lysates; SART 3 family antigens; SSX

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ARTICLE; CANCER CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; OSTEOSARCOMA; PRIORITY JOURNAL;

ANTIBODIES, BLOCKING; ANTIGENS, NEOPLASM; BONE NEOPLASMS; CELL EXTRACTS; CELL LINE, TUMOR; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; K562 CELLS; LYMPHOCYTE ACTIVATION; MONOCYTES; OSTEOSARCOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78649921873     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.09.007     Document Type: Article

References (31)

1. Fagioli F., Palmero A., Berger M., Gastaldo G., Pessolano R., Berta M., et al. Trattamento dell'osteosarcoma delle estremità ad alto grado di malignità, Minerva. Ortop Traumatol 2002, 53:195.
2. Bacci G., Picci P., Ferrari S. Primary chemotherapy and delayed surgery for non metastatic osteosarcoma of the extremities: results in 164 patients pre-operatively treated with high doses of methotrexate followed by Cisplatin and Doxorubicin. Cancer 1993, 72:3227-3238.
3. Saeter G., Alvegard T.A., Elomaa I., Stenwig A.E., Holmstrom T., Solheim O.P. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of pre-operative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group study. J Clin Oncol 1991, 9:1766-1775.
4. Saeter G., Wiebe T., Wiklund T., Monge O., Wahlqvist Y., Engström K., et al. Chemotherapy in osteosarcoma. The Scandinavian Sarcoma Group experience. Acta Orthop Scand Suppl 1999, 285:74-82.
5. Meyers P.A., Gorlick R., Heller G., Casper E., Lane J., Huvos A.G., et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 1998, 16:2452-2458.
6. Provisor A.J., Ettinger L.J., Nachman J.B., Krailo M.D., Makley J.T., Yunis E.J., et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 1997, 15:76-84.
7. Saeter G., Hoie J., Stenwig A.E., Johansson A.K., Hannisdal E., Solheim O.P. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995, 15:1084-1093.
8. Bacci G., Briccoli A., Ferrari S., Saeter G., Donati D., Longhi A. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide. Oncol Rep 2000, 7:339-346.
9. Fagioli F., Berger M., Brach del Prever A., Lioji S., Aglietta M., Ferrari S. Regression of metastatic osteosarcoma following non-myeloablative stem cell transplantation. A case report. Haematologica 2003, 88:ECR16.
10. Kounami S., Nakayama K., Yoshiyama M., Yoshimasu T., Aoyagi N., Yoshikawa N. Non-myeloablative allogenic peripheral blood stem cell transplantation in a patient with refractory osteosarcoma. Pediatr Transplant 2005, 9:342-345.
11. Fagioli F., Aglietta M., Tienghi A., Ferrari S., del Prever A.Brach, Vassallo E. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol 2003, 110:139-148.
12. Bollard C.M., Savoldo B., Rooney C.M., Heslop H.E. Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol 2003, 110:139-148.
13. Pardoll D. T-cells take aim at cancer. PNAS 2002, 99:15840-15842.
14. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6:1755-1766.
15. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004, 4:941-952.
16. De Plaen E., Arden K., Traversari C., Gaforio J.J., Szikora J.P., De Smet C., et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994, 40:360-369.
17. Sudo T., Kuramoto T., Komiya S., Inoue A., Itoh K. Expression of MAGE genes in osteosarcoma. J Orthop Res 1997, 15:128-132.
18. Tureci O., Chen Y.T., Sahin U., Gure A.O., Zwick C., Villena C., et al. Expression of SSX genes in human tumors. Int J Cancer 1998, 77:19-23.
19. Naka N., Araki N., Nakanishi H., Itoh K., Mano M., Ishiguro S. Expression of SSX genes in human osteosarcomas. Int J Cancer 2002, 98:640-642.
20. Yang D., Nakao M., Shichijo S., Sasatomi T., Takasu H., Matsumoto H. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999, 59:4056-4063.
21. Tsuda N., Murayama K., Ishida H., Matsunaga K., Komiya S., Itoh K., et al. Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res 2001, 19:346-351.
22. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
23. Straathof K.C., Bollard C.M., Rooney C.M., Heslop H.E. Immunotherapy for Epstein-Barr virus-associated cancers in children. Oncologist 2003, 8:83-98.
24. Dazzi F., Goldman J. Donor lymphocyte infusions. Curr Opin Hematol 1999, 6:394-399.
25. Dudley M.E., Rosenberg S.A. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003, 3:666-675.
26. Bakker A.B., Marland G., De Boer A.J., Huijbens R.J., Danen E.H., Adema G.J. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995, 55:5330-5334.
27. Fields R.C., Shimizu K., Mule J.J. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998, 95:9482-9487.
28. Abdel-Wahab Z., DeMatos P., Hester D., Dong X.D., Seigler H.F. Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide (280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. Cell Immunol 1998, 186:63-74.
29. Hao X., Shao Y., Ren X., Liu H., Xu Q., Li H. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients. J Cancer Res Clin Oncol 2002, 128:507-515.
30. Graff-Dubois S., Faure O., Gross D.A., Alves P., Scardino A., Chouaib S. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 2002, 169:575-580.
31. Sato M., Chamoto K., Nishimura T. A novel tumor-vaccine cell therapy using bone marrow-derived dendritic cell type 1 and antigen-specific Th1 cells. Int Immunol 2003, 15:837-843.